LOS ANGELES (February 16, 2016) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it recently has been issued U.S. Patent Nos. 9,200,303 and 9,226,933 by the U.S. Patent & Trademark Office.
U.S. Patent No. 9,200,303 covers the manufacturing processes for RP-G28 and is related to producing a high purity galacto-oligosaccharide (GOS). U.S. Patent No. 9,226,933 is related to a composition for ameliorating the symptoms of lactose intolerance. Subject to the payment of maintenance fees, these patents will remain in force until 2030 and 2024, respectively.
“As part of our strategy in the development of RP-G28, we have continued to build a strong patent portfolio surrounding the intellectual property of our innovative treatment for lactose intolerance,” Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals, stated. “With the addition of these two new patents, we now have seven issued U.S. patents in our portfolio, providing Ritter Pharmaceuticals with extensive protection of our intellectual property. With this additional patent protection, the company is well positioned as we enter our Phase 2b/3 trial.”
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.
This release may contain forward-looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.